En general se proponen las siguientes recomendaciones: - Los trabajadores sanitarios deberán extremar al máximo las medidas de higiene de manos con agua y jabón.- Se deben colocar una mascarilla quirúrgica durante el contacto con pacientes que presentan clínica respir...atoria (no sospechosa de coronavirus). - Antes de la atención de un paciente con síntomas respiratorios se le indicará que se coloque una mascarilla tipo quirúrgica - Procurar que los pacientes con clínica respiratoria usen mascarilla quirúrgica - Usar el equipo de protección individual (EPI) correspondiente cuando se atienda a pacientes sospechosos de coronavirus - Los profesionales sanitarios con fiebre o clínica respiratoria aguda se abstendrán de acudir a su puesto de trabajo hasta que se valore su situación.
more
27.03.2020
Various health experts on how to manage mental health and well-being during the #COVID19 outbreak.
WHO recommends member states provide universal access to public hand hygiene stations and making their use obligatory on entering and leaving any public or private commercial building and any public transport facility. It is also recommended that healthcare facilities improve access to and practice ...of hand hygiene.
more
Updated 10 August 2020
This document presents an essential medicines list (EML) to manage patients in intensive care units (ICUs) with suspected or confirmed COVID-19 diagnosis, which includes active ingredients with dosage form and concentration, and are preferably in the WHO Model Lists of Essent...ial Medicines 2019; based on clinical presentations and symptoms identified and prioritized in World Health Organization (WHO) and Surviving Sepsis Campaign (SSC) guidelines and the evidence presented in these guidelines.
more
10 July 2020
Guidance for authorities and event organizers planning mass gatherings during the current COVID-19 pandemic
The content of this Risk Assessment tool has been updated to reflect new WHO guidance and new evidence on both COVID-19 and mass gatherings, as well as feedback from end-users.
...
Additional improvements have been made to the way the information is organized and presented: the Decision Tree is now built into the tool and a new tab dedicated to Risk Communication has been added. The expanded tool now includes six tabs: 1. Instructions; 2. Decision Tree; 3. Risk Evaluation; 4. Risk Mitigation; 5. Decision Matrix; 6. Risk Communication.
more
PROGRAMME D’APPUI A LA RESILIENCE DES MENAGES POUR FAIRE FACE AUX CONSEQUENCESSOCIO-ECONOMIQUES DU COVID 19
This resource includes posters with key messages for older adults on how to take care of their well-being and how they can provide support to those around them during the COVID-19 pandemic and beyond. It includes instructions for facilitators of mental health and psychosocial support (MHPSS) on how ...to conduct guided conversations with older adults using these posters.
more
This report offers a summary of the provided support and recommendations on priority activities for IPC improvement at national and facility levels. The COVID-19 pandemic spotlighted areas for improvement in the IPC programme at national and facility levels. Improvements in the IPC programme were ac...hieved during the acute phase of the pandemic response. WHO will continue to support the Ministry Health of Ukraine and the Public Health Centre, as well as health facility managers and health-care providers, on the next steps to ensure the sustainability of progress achieved and to further enhance IPC in health-care settings.
more
Este artículo analiza un grupo particularmente vulnerable a la pandemia de la COVID-2019: las personas privadas de libertad (PPLs). Con base en el análisis del Censo Carcelario de 2019, presentamos la situación actual de las PPLs y las condiciones de los establecimient...os penitenciarios de Bolivia, con énfasis en los aspectos que impactan en la salud. Posteriormente, identificamos los principales factores estructurales detrás de la mayor vulnerabilidad epidemiológica y sanitaria de las PPLs, no solo a la COVID-2019, sino a epidemias en general. Diferentes instituciones involucradas en el combate de la pandemia desarrollaron recomendaciones para su prevención y tratamiento en contextos carcelarios. Considerando estas recomendaciones y los datos de la situación de las PPLs de Bolivia, desarrollamos propuestas de reformas políticas y legales para reducir la vulnerabilidad epidemiológica de esta población. Argumentamos que, mientras algunas son sencillas de implementar, muchas se enfrentan a obstáculos estructurales para su ejecución, demandando reformas profundas en la política carcelaria y el sistema penal.
more
sobre la base de las orientaciones actuales de la OMS, 31 de mayo de 2021. Memorando
This aide-mémoire presents information on use and procurement of masks for community outreach interventions, with a focus on those for malaria, neglected tropical diseases, tuberculosis, HIV/AIDS and vaccine-preve...ntable diseases. It details requirements for the different types of professionals involved (e.g. health workers, social mobilizers, data collectors, logisticians, insecticide spraying personnel, etc.), based on their level of risk of potential exposure to SARS-CoV-2.
more
orientaciones provisionales, 14 de junio de 2021
24 September 2021. The vaccine has been authorized by the Chinese National Regulatory Authority (NRA) – the National Medicinal Product Administration (NMPA) – as well as other regulatory authorities. Because WHO has granted Emergency Use Listing (EUL) for the COVID-19 Vaccine BIBP/ Sinopharm, th...e Africa Union and Africa CDC’s Regulatory Taskforce has endorsed the Emergency Use Authorization for the vaccine (see scenario #1) and the specification is 0.5ml/dose, 1 dose/vial; or 2 doses/vial; or 5 doses/vial. As such, African Union Member States are recommended to waive any review processes and rely directly on the WHO EUL via the AVAREF managed pathway described in Scenario #1.
more
24 September 2021. The vaccine has been authorized by the Chinese National Regulatory Authority (NRA) – the National Medicinal Product Administration (NMPA) – as well as other regulatory authorities. Because WHO has granted Emergency Use Listing (EUL) for the Sinovac COVID-19 vaccine (Vero Cell ...[Inactivated]) – CoronaVac, the Africa Union and Africa CDC’s Regulatory Taskforce has endorsed the Emergency Use Authorisation for the vaccine (see scenario #1). As such, African Union Member States are recommended to waive any review processes and rely directly on the WHO EUL via the AVAREF managed pathway described in Scenario #1
more
16 Dec. 2021
This document is a prioritization toolkit providing a set of action steps to follow in the event of an impending surge in cases of COVID-19 in health-care facilities. The document provides a framework for action steps to be followed within 2-4 weeks of identification of a surge or resu...rgence of cases, and is accompanied by references to existing WHO resources to assist with managing each step. This document is intended for emergency operations centre focal persons for health facilities, incident managers, health-care managers and administrators, and infection prevention and control focal persons.
more
Este documento realiza recomendaciones para la Supervisión de Salud Infantil en Atención Primaria de Salud, de manera de reorganizar y apoyar la eficiencia en la gestión de la oferta programática presencial ampliando la respuesta de acuerdo con la evolución de la pandemia. De esta forma, comple...menta las acciones señaladas en el documento “Orientación para la continuidad de la atención en APS en contexto de pandemia COVID-19” Ordinario N° 3991, diciembre 2020.
more
Annals of Medicine and Surgery, 79 (2022)104033
La dosis de refuerzo está indicada una vez transcurridos los 4 meses (120 días) de la última dosis del esquema inicial y será con vacuna de plataforma ARNm: Pfizer-BioNTech pediátrica a partir de los 5 años o Moderna para uso pediátrico a partir de los 6 años.
Los datos preliminares de eficacia se infirieron mediante un enfoque de “inmunogenicidad puente”, en el que los títulos neutralizantes obtenidos después de la vacuna en niños y niñas de 5 a 11 años se compararon con los títulos obtenidos en adolescentes de 16 a 25 años (en quienes se hab...a evaluado la eficacia).Entre los participantes sin evidencia de infección previa por SARS-CoV-2, hubo 3 casos de COVID-19 entre los 1.305 receptores de vacuna a partir de los 7 días de la segunda dosis y 16 entre los 663 receptores de placebo.
more
Infectious disease epidemics pose a threat to reproductive, maternal, newborn and child health (RMNCH) both directly—by worsening women’s and children’s health outcomes—and indirectly—by reducing their access to services.1–4 Greater investment is therefore needed to mitigate the negative... effects of COVID-19 and avoid a reversal of recent gains in RMNCH coverage and outcomes.1 However, COVID-19 has reduced household and government budgets,5 and there are concerns about the extent to which resources have been diverted away from RMNCH.
more